The 'NASA' Coca-Extract Stock Debuted at a Third of Its Own Financing Price

A company that turns coca leaves — with the cocaine stripped out — into food-and-beverage ingredients started trading on the Canadian Securities Exchange this past Thursday under the symbol NASA. The ticker has nothing to do with the space agency. It borrows the name of the Nasa Indigenous community in Colombia, whose exclusive license is the company's entire legal supply chain. Before you file this away as a novelty, there's a real number hiding under the brand, and it's doing most of the talking.

Power Leaves Holdings makes two proprietary ingredients, Coca Extract and Coca Essence, plus a fertilizer, for the global food-and-beverage trade. It claims what it calls the first-ever legal Colombian supply chain for decocainized coca extract, built on an exclusive license with the Nasa community of the Calderas reserve and processed through three facilities in the Neiva region, including an INVIMA-registered research site and an FDA-registered packaging plant. The management bench reads like a reunion of Canada's cannabis-extraction boom: CEO Pat McCutcheon is the co-founder and former chief of MediPharm Labs.

How a coca company became a ticker

NASA didn't take a conventional path to the market, and that history is part of the risk. On August 31 the private company Power Leaves pulled off a reverse takeover of Atmofizer Technologies, an already-listed CSE vehicle, through a three-cornered amalgamation. Atmofizer was no upstart either — it was itself created by a 2021 reverse takeover with Vaxxinator Enterprises, and before that it was Consolidated HCI Holdings.

That is what a reverse merger is to a beginner: a private operating company buys the empty public listing of an older, often dormant shell rather than filing for an IPO. The upside is speed and a ready trading vehicle. The trade-off is a shareholder base that inherits whatever governance and dilution baggage the shell carried — and, frequently, a float more suited to speculators than to long-term investors. A business that has changed corporate identity twice in five years deserves scrutiny before it gets your money.

The wedge the market already drew

Now the numbers, because this is where the story gets concrete. To fund the venture, Power Leaves sold subscription receipts at US$0.25 each, raising gross proceeds of US$3.16 million (about US$3.0 million net), each unit attached to a warrant exercisable at US$0.30 into August 2028. On listing the company had roughly 211 million shares outstanding — about 248 million fully diluted, after a grant of 20 million stock options at US$0.25 that vested immediately.

And the market's verdict on day one? The shares have been trading around C$0.11.

Stop there, because that single comparison is the whole thesis. The company priced its financing at US$0.25, and the public market is pricing the same equity at about C$0.11 — roughly a third of what subscribers paid on any plausible exchange rate, and far below the US$0.30 warrant strike, which is now deep out of the money. The investors who wrote the checks in March, April, and August are already underwater on the very first day of trading. Add the founders' own tell: insider shares are locked up for a year and release early only if the stock sustains a volume-weighted average of at least US$0.45 for five consecutive days — a price several times where it trades today.

A market cap around C$25 million on a business with no disclosed recurring revenue means the price is carrying the story, not the other way around.

Demand is not the stated problem — revenue is

To be fair, the underlying venture is not empty. It signed real agreements along the way: a first commercial order from an unnamed U.S. beverage manufacturer at US$100 per litre in mid-2023, a Canadian take-or-pay deal committing US$250,000 in its first year, and later a distribution partnership with the botanical-flavor firm Abstrax. Each one is genuine forward motion, but each is early-stage, and none of them produced disclosed revenue figures at the time of listing.

Management's own framing is the most useful sentence in the filing: demand, the CEO says, is not the constraint — the business has been limited by production capacity. Everything in the listing materials reinforces the same point, describing a commercial pipeline of flavor houses and consumer-packaged-goods companies that must still be "converted into recurring revenue via signed supply agreements."

That is the whole honest picture. There is no earnings number to hang a multiple on — no forward EPS, no consensus revenue — so this is not a discounted-growth entry where the math can be checked. The market sizes the company cites, like a US$232 billion carbonated-beverage market and a US$283 billion U.S. alcoholic-beverage market, are total addressable pools, not revenue any single Colombian ingredient supplier will capture.

The single metric that turns this from speculation into an investment is reported revenue. If capacity truly is the binding constraint and the signed pipeline really exists, the roughly US$3 million of new capital should start showing up as disclosed, recurring sales volume in future financial statements. The moment that happens, there is something to anchor a valuation to. Until then, what you're buying is a well-named, well-connected commercial bet on a coca-extract ingredient market, priced below what the people who funded it paid — and far below what its own insiders think their shares are worth.